MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding MoonLake Immunotherapeutics changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 83 | 1 | 118 | +36 |
| Shares | 56.1M | 894.0K | 56.3M | +1.16M (+2.1%) |
| Value | $2.86B | $45.6M | $3.21B | +$397.1M (+14.1%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (47)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (11)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Banque Pictet & Cie SA | 640,000 | $32.6M |
| Artal Group S.A. | 400,000 | $20.4M |
| Paradigm Biocapital Advisors LP | 369,615 | $18.9M |
| Silverarc Capital Management, LLC | 200,000 | $10.2M |
| Deep Track Capital, LP | 108,450 | $5.53M |
| Jefferies Financial Group Inc. | 93,789 | $4.78M |
| Hudson Bay Capital Management LP | 60,000 | $3.06M |
| Alyeska Investment Group, L.P. | 57,347 | $2.92M |
| Ergoteles LLC | 38,617 | $1.97M |
| Shay Capital LLC | 9,500 | $484.5K |
| Connor, Clark & Lunn Investment Management Ltd. | 9,421 | $480.5K |
Not filed for Q3 2023 yet (1)
Institutions that held MoonLake Immunotherapeutics at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 894,005 | $45.6M |